On August 11, 2026, the clinical trial registry listed an update for a study involving degarelix. The trial, titled "Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer," is registered under identifier NCT01786265. The study is a Phase 2 trial. Its current status is listed as active, not recruiting. This status indicates the trial is ongoing but is no longer enrolling new participants. The trial examines finite androgen ablation approaches, with degarelix as part of the treatment regimen being studied, in patients with recurrent prostate cancer. No results have been reported as part of this update. The registry entry does not include efficacy or safety findings at this time. Readers seeking further procedural details can consult the official trial registry listing for status definitions and study design information. For general background on degarelix, including its approved regulatory status and other context, readers can refer to the compound overview.
Degarelix Trial NCT01786265 Now Active, Not Recruiting as of Aug 2026
See the full degarelix overview
Source: https://clinicaltrials.gov/study/NCT01786265